Latexin Antikörper (C-Term)
Kurzübersicht für Latexin Antikörper (C-Term) (ABIN966502)
Target
Alle Latexin (LXN) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
- 
    - 
                                            Bindungsspezifität
- C-Term
- 
                                            Immunogen
- Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to C-terminal residues of human LXN (Latexin)
 
- 
                                            
- 
    
- 
    - 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Lagerung
- 4 °C
 
- 
                                            
- 
    - 
                                            : "Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin."    in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, Issue 11, pp. 3978-83, (2005)         (PubMed).        
 
 
- 
                                            : "Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin."    in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, Issue 11, pp. 3978-83, (2005)         (PubMed).        
- 
    - Latexin (LXN)
- 
                                            Andere Bezeichnung
- LXN
- 
                                            Hintergrund
- 
                        LXN (Latexin) is a hardly reversible, non-competitive, and potent inhibitor of CPA1, CPA2 and CPA4. LXN (Latexin) is likely a cytoplasm protein and it is highly expressed in heart, prostate, ovary, kidney, pancreas, and colon, moderate or low in other tissues including brain. LXN (Latexin) belongs to the protease inhibitor I47 (latexin) family.
 Synonyms: ECI (Endogenous carboxypeptidase inhibitor), TCI (Tissue carboxypeptidase inhibitor), MUM
 Target
- 
                    
 
                                     
                                     
                                    